1 min read
Add as a preferred source on GoogleRezolute Reports 13 of 16 Patients Achieved at Least 50% Glucose Infusion Rate Reduction
The Phase 3 upLIFT study is evaluating ersodetug for tumor hyperinsulinism.
Rezolute announced preliminary interim results from its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism; 13 of 16 patients achieved at least a 50% reduction in glucose infusion rate from baseline.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.